<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02899988</url>
  </required_header>
  <id_info>
    <org_study_id>16481</org_study_id>
    <secondary_id>I6T-MC-AMAF</secondary_id>
    <secondary_id>2016-001098-34</secondary_id>
    <nct_id>NCT02899988</nct_id>
  </id_info>
  <brief_title>A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Plaque Psoriasis</brief_title>
  <official_title>A Phase 2, Multicenter, Randomized, Parallel-Arm, Placebo- Controlled Study of LY3074828 in Subjects With Moderate-to- Severe Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the efficacy of the study drug mirikizumab in
      participants with moderate to severe plaque psoriasis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 14, 2016</start_date>
  <completion_date type="Actual">May 8, 2019</completion_date>
  <primary_completion_date type="Actual">June 19, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With a ≥90% Improvement in Psoriasis Area and Severity Index (PASI 90)</measure>
    <time_frame>Week 16</time_frame>
    <description>PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of scaling, redness, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis (PsO) to 72 for the most severe disease. For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region * area score * weighing factor [head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)]. Overall scores range from 0 (no PsO) to 72 (the most severe disease).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a 100% Improvement in Psoriasis Area and Severity Index (PASI 100)</measure>
    <time_frame>Week 16</time_frame>
    <description>The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of scaling, redness, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no PsO to 72 for the most severe disease. For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region * area score * weighing factor [head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)]. Overall scores range from 0 (no PsO) to 72 (the most severe disease).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a ≥75% Improvement in Psoriasis Area and Severity Index (PASI 75)</measure>
    <time_frame>Week 16</time_frame>
    <description>The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of scaling, redness, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no PsO to 72 for the most severe disease. For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region * area score * weighing factor [head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)]. Overall scores range from 0 (no PsO) to 72 (the most severe disease).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Static Physician Global Assessment (sPGA) 0 and 0/1</measure>
    <time_frame>Week 16</time_frame>
    <description>The sPGA is the physician's determination of the participant's PsO lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participant's PsO was assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe). An sPGA responder was defined as having a post-baseline sPGA score of &quot;0&quot; or &quot;1&quot; with at least a 2-point improvement from baseline. Participants who did not meet the clinical response criteria or had missing data at Week 16 were considered non-responders for non-responder Imputation (NRI) analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline on the Psoriasis Symptom Scale (PSS) Total Score</measure>
    <time_frame>Baseline, Week 16</time_frame>
    <description>PSS is a patient-administered assessment of 4 symptoms (itch, pain, stinging, and burning); 3 signs (redness, scaling, and cracking); and 1 item on the discomfort related to symptoms/signs. The overall severity for each individual symptom/sign from the patient's psoriasis is indicated by selecting the number from a numeric rating scale (NRS) of 0 to 10 that best describes the worst level of each symptom/sign in the past 24 hours, where 0=no symptom/sign and 10=worst imaginable symptom/sign. The total score was calculated by summing the 8 individual items and ranged from 0 to 80, higher scores indicated greater symptom/sign severity. Least Square(LS) Mean was calculated using Mixed Model Repeated Measures (MMRM) model with treatment, geographic region [United States/Outside United States (US/OUS)], previous therapy (yes/no), baseline value, visit, and the interaction treatment-by-visit as fixed factors, covariance structure = heterogeneous autoregressive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change (Improvement) From Baseline on the Patient Global Assessment</measure>
    <time_frame>Baseline, Week 16</time_frame>
    <description>The Patient's Global Assessment of Disease Severity is a single-item participant-reported outcome measure on which participants are asked to rate the severity of their psoriasis &quot;today&quot; from 0 (Clear) = no psoriasis, to 5 (Severe) = the worst their psoriasis has ever been. Least Square (LS) Mean was calculated using Mixed Model Repeated Measures (MMRM) model with treatment, geographic region (US/OUS), previous therapy (yes/no), baseline value, visit, and the interaction treatment-by-visit as fixed factors, covariance structure = unstructured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline on the Dermatology Life Quality Index (DLQI) Total Score</measure>
    <time_frame>Baseline, Week 16</time_frame>
    <description>The DLQI is a patient-reported, 10-question, quality-of-life questionnaire that covers 6 domains including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include &quot;Not at all,&quot; &quot;A little,&quot; &quot;A lot,&quot; and &quot;Very much,&quot; with corresponding scores of 0, 1, 2, and 3 respectively. Questions 3-10 also have an additional response category of &quot;Not relevant&quot; which is scored as &quot;0&quot;. For all questions, if unanswered the question is scored as &quot;0&quot;. Totals range from 0 to 30 (less to more impairment). Least Square (LS) Mean was calculated using Mixed Model Repeated Measures (MMRM) model with treatment, geographic region (US/OUS), previous therapy (yes/no), baseline value, visit, and the interaction treatment-by-visit as fixed factors, covariance structure = unstructured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline on the 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) and Mental Component Summary (MCS) Scores</measure>
    <time_frame>Baseline, Week 16</time_frame>
    <description>The SF-36 is a health-related survey that assesses participant's quality of life and consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems and emotional problems, general health, mental health, social functioning, vitality, and 2 component scores (MCS and PCS). MCS consisted of social functioning, vitality, mental health, and role-emotional scales. PCS consisted of physical functioning, bodily pain, role-physical, and general health scales. Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with higher scores indicating better health status or functioning. Least Squares Mean (LS Mean) was calculated using Analysis of covariance (ANCOVA) model with treatment, geographic region (US/OUS), and previous therapy (yes/no) as fixed factors and baseline value as covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Curve (AUC) of Mirikizumab From Baseline Through Week 104</measure>
    <time_frame>Week 0, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 32, Week 40, Week 48, Week 52, Week 56, Week 64, Week 72, Week 80, Week 88, Week 96, Week 100, Week 104</time_frame>
    <description>Pharmacokinetics (PK): Area Under the Curve (AUC) of Mirikizumab From Baseline through Week 104</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">205</enrollment>
  <condition>Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>30 mg Mirikizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 mg Mirikizumab administered subcutaneously (SC) every 8 weeks (Q8W).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100 mg Mirikizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg Mirikizumab administered SC Q8W.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>300 mg Mirikizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 mg Mirikizumab administered SC Q8W.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered SC Q8W.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mirikizumab</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>100 mg Mirikizumab</arm_group_label>
    <arm_group_label>30 mg Mirikizumab</arm_group_label>
    <arm_group_label>300 mg Mirikizumab</arm_group_label>
    <other_name>LY3074828</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Present with chronic plaque psoriasis based on an investigator confirmed diagnosis of
             chronic psoriasis vulgaris for at least 6 months prior to baseline and meet the
             following criteria:

               -  plaque psoriasis involving ≥10% body surface area (BSA) and absolute PASI score
                  ≥12 in affected skin at screening and baseline

               -  sPGA score of ≥3 at screening and baseline

          -  Candidate for biologic treatment for psoriasis.

        Exclusion Criteria:

          -  Have a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal,
             endocrine, hematological, neurological, or neuropsychiatric disorders or any other
             serious and/or unstable illness that, in the opinion of the investigator, could
             constitute a risk when taking investigational product or could interfere with the
             interpretation of data.

          -  Breastfeeding or nursing (lactating) women.

          -  Have had serious, opportunistic, or chronic/recurring infection within 6 months prior
             to screening.

          -  Have received live vaccine(s) (included attenuated live vaccines) within 1 month of
             screening or intend to during the study.

          -  Have any other skin conditions (excluding psoriasis) that would affect interpretation
             of the results.

          -  Have received systemic nonbiologic psoriasis therapy or phototherapy within 28 days
             prior to baseline.

          -  Have received topical psoriasis treatment within 14 days prior to baseline.

          -  Have received anti-tumor necrosis factor (TNF) biologics, or anti-interleukin (IL)-17
             targeting biologics within 8 weeks prior to baseline.

          -  Have previous exposure to any biologic therapy targeting IL-23 (including
             ustekinumab), either licensed or investigational (previous briakinumab use is
             permitted).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Renstar Medical Research</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forward Clinical Trials, Inc</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33624</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Indiana Clinical Trials Center, PC</name>
      <address>
        <city>Plainfield</city>
        <state>Indiana</state>
        <zip>46168</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The South Bend Clinic</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DS Research</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Shondra Smith MD</name>
      <address>
        <city>Lake Charles</city>
        <state>Louisiana</state>
        <zip>70605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Dermatology PC</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psoriasis Treatment Center of Central New Jersey</name>
      <address>
        <city>East Windsor</city>
        <state>New Jersey</state>
        <zip>08520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Dermatology and Research Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Partners LLC</name>
      <address>
        <city>Johnston</city>
        <state>Rhode Island</state>
        <zip>02919</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Menter Dermatology Research Institute</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Associates</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.</name>
      <address>
        <city>Calgary</city>
        <zip>T2G 1B1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.</name>
      <address>
        <city>Halifax</city>
        <zip>B3H1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.</name>
      <address>
        <city>Montreal</city>
        <zip>H2K4L5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.</name>
      <address>
        <city>Peterborough</city>
        <zip>K9J 5K2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.</name>
      <address>
        <city>Richmond Hill</city>
        <zip>L4B 1A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.</name>
      <address>
        <city>Waterloo</city>
        <zip>N2J 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hamburg</city>
        <zip>20354</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mahlow</city>
        <zip>15831</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Gifu</city>
        <zip>501-1194</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kurume</city>
        <zip>830-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Morioka</city>
        <zip>020-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nagoya</city>
        <zip>467-8602</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Osaka</city>
        <zip>545-8586</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Shinagawa-KU</city>
        <zip>141-8625</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Shinjuku-ku</city>
        <zip>169-0073</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Takaoka-shi</city>
        <zip>9330871</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tsu-shi</city>
        <zip>514-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bialystok</city>
        <zip>15-017</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bialystok</city>
        <zip>15-351</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lodz</city>
        <zip>90-242</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lodz</city>
        <zip>90-265</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Swidnik</city>
        <zip>21-040</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Warsaw</city>
        <zip>01-518</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Warszawa</city>
        <zip>02-507</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Wroclaw</city>
        <zip>51-318</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grupo Dermatologico de Carolina</name>
      <address>
        <city>Carolina</city>
        <zip>00985</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ponce School of Medicine CAIMED Center</name>
      <address>
        <city>Ponce</city>
        <zip>00716</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>Japan</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 15, 2019</verification_date>
  <study_first_submitted>September 9, 2016</study_first_submitted>
  <study_first_submitted_qc>September 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2016</study_first_posted>
  <results_first_submitted>May 5, 2020</results_first_submitted>
  <results_first_submitted_qc>June 5, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 18, 2020</results_first_posted>
  <disposition_first_submitted>June 1, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>June 1, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">June 7, 2018</disposition_first_posted>
  <last_update_submitted>June 5, 2020</last_update_submitted>
  <last_update_submitted_qc>June 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IL-23</keyword>
  <keyword>dermatology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.</ipd_time_frame>
    <ipd_access_criteria>A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org/</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 21, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/88/NCT02899988/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 28, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/88/NCT02899988/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Induction: Placebo</title>
          <description>Induction: Participants received placebo subcutaneously (SC) every 8 weeks (Q8W) during Induction period.</description>
        </group>
        <group group_id="P2">
          <title>Induction: 30 mg Mirikizumab Q8W</title>
          <description>Induction: Participants received 30 milligram (mg) mirikizumab SC Q8W during Induction period.</description>
        </group>
        <group group_id="P3">
          <title>Induction:100 mg Mirikizumab Q8W</title>
          <description>Induction: Participants received 100 mg mirikizumab SC Q8W during Induction period.</description>
        </group>
        <group group_id="P4">
          <title>Induction: 300 mg Mirikizumab Q8W</title>
          <description>Induction: Participants received 300 mg mirikizumab SC Q8W during Induction period.</description>
        </group>
        <group group_id="P5">
          <title>Maintenance: 30 mg Mirikizumab Q8W to 30 mg Mirikizumab PRN</title>
          <description>Maintenance:
Participants received 30 mg mirikizumab as needed (PRN) during the maintenance period.
Participants who had greater than or equal to (≥) Psoriasis Area and Severity Index (PASI) 90 at Week 16 after receiving 30 mg mirikizumab Q8W during induction period.
Follow-up: participants did not receive drug during the follow-up period.</description>
        </group>
        <group group_id="P6">
          <title>Maintenance: 100 mg Mirikizumab Q8W to 100 mg Mirikizumab PRN</title>
          <description>Maintenance:
Participants received 100 mg mirikizumab as needed (PRN) during the maintenance period.
Participants had ≥ PASI 90 at Week 16 after receiving 100 mg mirikizumab Q8W during induction period.
Follow-up: participants did not receive drug during the follow-up period.</description>
        </group>
        <group group_id="P7">
          <title>Maintenance: 300 mg Mirikizumab Q8W to 300 mg Mirikizumab PRN</title>
          <description>Maintenance:
Participants received 300 mg mirikizumab as needed (PRN) during the maintenance period.
Participants had ≥ PASI 90 at Week 16 after receiving 300 mg mirikizumab Q8W during induction period.
Follow-up: participants did not receive drug during the follow-up period.</description>
        </group>
        <group group_id="P8">
          <title>Maintenance: Placebo to 300 mg Mirikizumab Q8W</title>
          <description>Maintenance:
Participants received 300 mg mirikizumab Q8W during the maintenance period. Participants had received placebo during induction period.
Follow-up: Participants did not receive drug during the follow-up period.</description>
        </group>
        <group group_id="P9">
          <title>Maintenance: 30 mg Mirikizumab Q8W to 300 mg Mirikizumab Q8W</title>
          <description>Maintenance:
Participants received 300 mg mirikizumab Q8W during the maintenance period. Participants had less than (&lt;) PASI 90 at Week 16 after receiving 30 mg mirikizumab Q8W during induction period.
Follow-up: Participants did not receive drug during the follow-up period.</description>
        </group>
        <group group_id="P10">
          <title>Maintenance: 100 mg Mirikizumab Q8W to 300 mg MirikizumabQ8W</title>
          <description>Maintenance:
Participants received 300 mg mirikizumab Q8W during the maintenance period. Participants had &lt; PASI 90 at Week 16 after receiving 100 mg mirikizumab Q8W during induction period.
Follow-up: participants did not receive drug during the follow-up period.</description>
        </group>
        <group group_id="P11">
          <title>Maintenance: 300 mg Mirikizumab Q8W</title>
          <description>Maintenance:
Participants who had &lt; PASI 90 at Week 16 continued to receive 300 mg mirikizumab SC Q8W during maintenance period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Induction Period (16 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="51"/>
                <participants group_id="P3" count="51"/>
                <participants group_id="P4" count="51"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least One Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="51"/>
                <participants group_id="P3" count="51"/>
                <participants group_id="P4" count="51"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="49"/>
                <participants group_id="P3" count="51"/>
                <participants group_id="P4" count="49"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Maintenance Period (88 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">No participants received placebo during maintenance period.</participants>
                <participants group_id="P2" count="0">No participants received 30 mg mirikizumab Q8W in both induction and maintenance.</participants>
                <participants group_id="P3" count="0">No participants received 100 mg mirikizumab Q8W in both induction and maintenance.</participants>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="15">Participants received 30 mg mirikizumab Q8W during induction period.</participants>
                <participants group_id="P6" count="30">Participants received 100 mg mirikizumab Q8W during induction period.</participants>
                <participants group_id="P7" count="34">Participants received 300 mg mirikizumab Q8W during induction period.</participants>
                <participants group_id="P8" count="50">Participants received placebo during induction period.</participants>
                <participants group_id="P9" count="34">Participants received 30 mg mirikizumab Q8W during induction arm.</participants>
                <participants group_id="P10" count="21">Participants received 100 mg mirikizumab Q8W during induction arm.</participants>
                <participants group_id="P11" count="15">Participants received 300 mg mirikizumab Q8W during induction arm.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Rescue Participants</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="10">In PRN not regaining ≥ PASI 90 after 3 consecutive doses of drug or have &lt; PASI 50 after 1 dose.</participants>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Roll Over to AMAH (NCT03556202)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="13"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="18"/>
                <participants group_id="P7" count="26"/>
                <participants group_id="P8" count="42"/>
                <participants group_id="P9" count="24"/>
                <participants group_id="P10" count="17"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="13"/>
                <participants group_id="P6" count="27"/>
                <participants group_id="P7" count="30"/>
                <participants group_id="P8" count="45"/>
                <participants group_id="P9" count="30"/>
                <participants group_id="P10" count="19"/>
                <participants group_id="P11" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="4"/>
                <participants group_id="P8" count="5"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Follow-Up (16 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2">Not all participants that completed maintenance period continued to follow-up period.</participants>
                <participants group_id="P6" count="4">Not all participants that completed maintenance period continued to follow-up period.</participants>
                <participants group_id="P7" count="3">Not all participants that completed maintenance period continued to follow-up period.</participants>
                <participants group_id="P8" count="3">Not all participants that completed maintenance period continued to follow-up period.</participants>
                <participants group_id="P9" count="6">Not all participants that completed maintenance period continued to follow-up period.</participants>
                <participants group_id="P10" count="2">Not all participants that completed maintenance period continued to follow-up period.</participants>
                <participants group_id="P11" count="0">Not all participants that completed maintenance period continued to follow-up period.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="6"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants who received at least one dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Induction: Placebo</title>
          <description>Induction: Placebo administered SC Q8W during Induction period.</description>
        </group>
        <group group_id="B2">
          <title>Induction: 30 mg Mirikizumab</title>
          <description>Induction: 30 mg Mirikizumab administered SC Q8W during Induction period.</description>
        </group>
        <group group_id="B3">
          <title>Induction: 100 mg Mirikizumab</title>
          <description>Induction: 100 mg Mirikizumab administered SC Q8W during Induction period.</description>
        </group>
        <group group_id="B4">
          <title>Induction: 300 mg Mirikizumab</title>
          <description>Induction: 300 mg Mirikizumab administered SC Q8W during Induction period.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="52"/>
            <count group_id="B2" value="51"/>
            <count group_id="B3" value="51"/>
            <count group_id="B4" value="51"/>
            <count group_id="B5" value="205"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.0" spread="12.39"/>
                    <measurement group_id="B2" value="49.2" spread="13.28"/>
                    <measurement group_id="B3" value="46.0" spread="13.18"/>
                    <measurement group_id="B4" value="47.5" spread="13.23"/>
                    <measurement group_id="B5" value="47.2" spread="12.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="36"/>
                    <measurement group_id="B5" value="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="42"/>
                    <measurement group_id="B5" value="160"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="41"/>
                    <measurement group_id="B4" value="42"/>
                    <measurement group_id="B5" value="170"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="23"/>
                    <measurement group_id="B5" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With a ≥90% Improvement in Psoriasis Area and Severity Index (PASI 90)</title>
        <description>PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of scaling, redness, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis (PsO) to 72 for the most severe disease. For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region * area score * weighing factor [head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)]. Overall scores range from 0 (no PsO) to 72 (the most severe disease).</description>
        <time_frame>Week 16</time_frame>
        <population>All participants who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Induction: Placebo</title>
            <description>Induction: Placebo administered SC Q8W during Induction period.</description>
          </group>
          <group group_id="O2">
            <title>Induction: 30 mg Mirikizumab</title>
            <description>Induction: 30 mg Mirikizumab administered SC Q8W during Induction period.</description>
          </group>
          <group group_id="O3">
            <title>Induction: 100 mg Mirikizumab</title>
            <description>Induction: 100 mg Mirikizumab administered SC Q8W during Induction period.</description>
          </group>
          <group group_id="O4">
            <title>Induction: 300 mg Mirikizumab</title>
            <description>Induction: 300 mg Mirikizumab administered SC Q8W during Induction period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a ≥90% Improvement in Psoriasis Area and Severity Index (PASI 90)</title>
          <description>PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of scaling, redness, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis (PsO) to 72 for the most severe disease. For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region * area score * weighing factor [head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)]. Overall scores range from 0 (no PsO) to 72 (the most severe disease).</description>
          <population>All participants who received at least one dose of study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="29.4" lower_limit="16.9" upper_limit="41.9"/>
                    <measurement group_id="O3" value="58.8" lower_limit="45.3" upper_limit="72.3"/>
                    <measurement group_id="O4" value="66.7" lower_limit="53.7" upper_limit="79.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.009</p_value>
            <method>Regression, Logistic</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>29.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>16.9</ci_lower_limit>
            <ci_upper_limit>41.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>58.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>45.3</ci_lower_limit>
            <ci_upper_limit>72.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>66.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>53.7</ci_lower_limit>
            <ci_upper_limit>79.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a 100% Improvement in Psoriasis Area and Severity Index (PASI 100)</title>
        <description>The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of scaling, redness, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no PsO to 72 for the most severe disease. For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region * area score * weighing factor [head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)]. Overall scores range from 0 (no PsO) to 72 (the most severe disease).</description>
        <time_frame>Week 16</time_frame>
        <population>All participants who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Induction: Placebo</title>
            <description>Induction: Placebo administered SC Q8W during Induction period.</description>
          </group>
          <group group_id="O2">
            <title>Induction: 30 mg Mirikizumab</title>
            <description>Induction: 30 mg Mirikizumab administered SC Q8W during Induction period.</description>
          </group>
          <group group_id="O3">
            <title>Induction: 100 mg Mirikizumab</title>
            <description>Induction: 100 mg Mirikizumab administered SC Q8W during Induction period.</description>
          </group>
          <group group_id="O4">
            <title>Induction: 300 mg Mirikizumab</title>
            <description>Induction: 300 mg Mirikizumab administered SC Q8W during Induction period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a 100% Improvement in Psoriasis Area and Severity Index (PASI 100)</title>
          <description>The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of scaling, redness, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no PsO to 72 for the most severe disease. For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region * area score * weighing factor [head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)]. Overall scores range from 0 (no PsO) to 72 (the most severe disease).</description>
          <population>All participants who received at least one dose of study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="15.7" lower_limit="5.7" upper_limit="25.7"/>
                    <measurement group_id="O3" value="31.4" lower_limit="18.6" upper_limit="44.1"/>
                    <measurement group_id="O4" value="31.4" lower_limit="18.6" upper_limit="44.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.039</p_value>
            <method>Regression, Logistic</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>15.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.7</ci_lower_limit>
            <ci_upper_limit>25.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.007</p_value>
            <method>Regression, Logistic</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>31.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>18.6</ci_lower_limit>
            <ci_upper_limit>44.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.007</p_value>
            <method>Regression, Logistic</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>31.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>18.6</ci_lower_limit>
            <ci_upper_limit>44.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a ≥75% Improvement in Psoriasis Area and Severity Index (PASI 75)</title>
        <description>The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of scaling, redness, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no PsO to 72 for the most severe disease. For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region * area score * weighing factor [head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)]. Overall scores range from 0 (no PsO) to 72 (the most severe disease).</description>
        <time_frame>Week 16</time_frame>
        <population>All participants who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Induction: Placebo</title>
            <description>Induction: Placebo administered SC Q8W during Induction period.</description>
          </group>
          <group group_id="O2">
            <title>Induction: 30 mg Mirikizumab</title>
            <description>Induction: 30 mg Mirikizumab administered SC Q8W during Induction period.</description>
          </group>
          <group group_id="O3">
            <title>Induction: 100 mg Mirikizumab</title>
            <description>Induction: 100 mg Mirikizumab administered SC Q8W during Induction period.</description>
          </group>
          <group group_id="O4">
            <title>Induction: 300 mg Mirikizumab</title>
            <description>Induction: 300 mg Mirikizumab administered SC Q8W during Induction period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a ≥75% Improvement in Psoriasis Area and Severity Index (PASI 75)</title>
          <description>The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of scaling, redness, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no PsO to 72 for the most severe disease. For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region * area score * weighing factor [head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)]. Overall scores range from 0 (no PsO) to 72 (the most severe disease).</description>
          <population>All participants who received at least one dose of study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" lower_limit="0" upper_limit="9.1"/>
                    <measurement group_id="O2" value="52.9" lower_limit="39.2" upper_limit="66.6"/>
                    <measurement group_id="O3" value="78.4" lower_limit="67.1" upper_limit="89.7"/>
                    <measurement group_id="O4" value="74.5" lower_limit="62.5" upper_limit="86.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>22.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.62</ci_lower_limit>
            <ci_upper_limit>89.97</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>74.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>62.1</ci_lower_limit>
            <ci_upper_limit>87.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>70.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>57.6</ci_lower_limit>
            <ci_upper_limit>83.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Static Physician Global Assessment (sPGA) 0 and 0/1</title>
        <description>The sPGA is the physician's determination of the participant's PsO lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participant's PsO was assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe). An sPGA responder was defined as having a post-baseline sPGA score of &quot;0&quot; or &quot;1&quot; with at least a 2-point improvement from baseline. Participants who did not meet the clinical response criteria or had missing data at Week 16 were considered non-responders for non-responder Imputation (NRI) analysis.</description>
        <time_frame>Week 16</time_frame>
        <population>All participants who received at least one dose of drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Induction: Placebo</title>
            <description>Induction: Placebo administered SC Q8W during Induction period.</description>
          </group>
          <group group_id="O2">
            <title>Induction: 30 mg Mirikizumab</title>
            <description>Induction: 30 mg Mirikizumab administered SC Q8W during Induction period.</description>
          </group>
          <group group_id="O3">
            <title>Induction: 100 mg Mirikizumab</title>
            <description>Induction: 100 mg Mirikizumab administered SC Q8W during Induction period.</description>
          </group>
          <group group_id="O4">
            <title>Induction: 300 mg Mirikizumab</title>
            <description>Induction: 300 mg Mirikizumab administered SC Q8W during Induction period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Static Physician Global Assessment (sPGA) 0 and 0/1</title>
          <description>The sPGA is the physician's determination of the participant's PsO lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participant's PsO was assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe). An sPGA responder was defined as having a post-baseline sPGA score of &quot;0&quot; or &quot;1&quot; with at least a 2-point improvement from baseline. Participants who did not meet the clinical response criteria or had missing data at Week 16 were considered non-responders for non-responder Imputation (NRI) analysis.</description>
          <population>All participants who received at least one dose of drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>sPGA (0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="15.7" lower_limit="5.7" upper_limit="25.7"/>
                    <measurement group_id="O3" value="31.4" lower_limit="18.6" upper_limit="44.1"/>
                    <measurement group_id="O4" value="31.4" lower_limit="18.6" upper_limit="44.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sPGA (0/1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="0" upper_limit="5.7"/>
                    <measurement group_id="O2" value="37.3" lower_limit="24.0" upper_limit="50.5"/>
                    <measurement group_id="O3" value="70.6" lower_limit="58.1" upper_limit="83.1"/>
                    <measurement group_id="O4" value="68.6" lower_limit="55.9" upper_limit="81.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>sPGA (0)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.041</p_value>
            <method>Regression, Logistic</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>15.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.7</ci_lower_limit>
            <ci_upper_limit>25.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>sPGA (0)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.007</p_value>
            <method>Regression, Logistic</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>31.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>18.6</ci_lower_limit>
            <ci_upper_limit>44.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>sPGA (0)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.008</p_value>
            <method>Regression, Logistic</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>31.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>18.6</ci_lower_limit>
            <ci_upper_limit>44.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>sPGA (0/1)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>35.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>21.5</ci_lower_limit>
            <ci_upper_limit>49.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>sPGA (0/1)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>68.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>55.6</ci_lower_limit>
            <ci_upper_limit>81.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>sPGA (0/1)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>66.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>53.4</ci_lower_limit>
            <ci_upper_limit>80.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline on the Psoriasis Symptom Scale (PSS) Total Score</title>
        <description>PSS is a patient-administered assessment of 4 symptoms (itch, pain, stinging, and burning); 3 signs (redness, scaling, and cracking); and 1 item on the discomfort related to symptoms/signs. The overall severity for each individual symptom/sign from the patient's psoriasis is indicated by selecting the number from a numeric rating scale (NRS) of 0 to 10 that best describes the worst level of each symptom/sign in the past 24 hours, where 0=no symptom/sign and 10=worst imaginable symptom/sign. The total score was calculated by summing the 8 individual items and ranged from 0 to 80, higher scores indicated greater symptom/sign severity. Least Square(LS) Mean was calculated using Mixed Model Repeated Measures (MMRM) model with treatment, geographic region [United States/Outside United States (US/OUS)], previous therapy (yes/no), baseline value, visit, and the interaction treatment-by-visit as fixed factors, covariance structure = heterogeneous autoregressive.</description>
        <time_frame>Baseline, Week 16</time_frame>
        <population>All participants who received at least one dose of study drug who had baseline and at least one post-baseline PSS observation.</population>
        <group_list>
          <group group_id="O1">
            <title>Induction: Placebo</title>
            <description>Induction: Placebo administered SC Q8W during Induction period.</description>
          </group>
          <group group_id="O2">
            <title>Induction: 30 mg Mirikizumab</title>
            <description>Induction: 30 mg Mirikizumab administered SC Q8W during Induction period.</description>
          </group>
          <group group_id="O3">
            <title>Induction: 100 mg Mirikizumab</title>
            <description>Induction: 100 mg Mirikizumab administered SC Q8W during Induction period.</description>
          </group>
          <group group_id="O4">
            <title>Induction: 300 mg Mirikizumab</title>
            <description>Induction: 300 mg Mirikizumab administered SC Q8W during Induction period.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline on the Psoriasis Symptom Scale (PSS) Total Score</title>
          <description>PSS is a patient-administered assessment of 4 symptoms (itch, pain, stinging, and burning); 3 signs (redness, scaling, and cracking); and 1 item on the discomfort related to symptoms/signs. The overall severity for each individual symptom/sign from the patient's psoriasis is indicated by selecting the number from a numeric rating scale (NRS) of 0 to 10 that best describes the worst level of each symptom/sign in the past 24 hours, where 0=no symptom/sign and 10=worst imaginable symptom/sign. The total score was calculated by summing the 8 individual items and ranged from 0 to 80, higher scores indicated greater symptom/sign severity. Least Square(LS) Mean was calculated using Mixed Model Repeated Measures (MMRM) model with treatment, geographic region [United States/Outside United States (US/OUS)], previous therapy (yes/no), baseline value, visit, and the interaction treatment-by-visit as fixed factors, covariance structure = heterogeneous autoregressive.</description>
          <population>All participants who received at least one dose of study drug who had baseline and at least one post-baseline PSS observation.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.35" spread="2.29"/>
                    <measurement group_id="O2" value="-31.19" spread="2.34"/>
                    <measurement group_id="O3" value="-42.33" spread="2.37"/>
                    <measurement group_id="O4" value="-33.66" spread="2.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-26.84</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.26</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-37.99</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.29</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-29.32</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>3.22</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change (Improvement) From Baseline on the Patient Global Assessment</title>
        <description>The Patient's Global Assessment of Disease Severity is a single-item participant-reported outcome measure on which participants are asked to rate the severity of their psoriasis &quot;today&quot; from 0 (Clear) = no psoriasis, to 5 (Severe) = the worst their psoriasis has ever been. Least Square (LS) Mean was calculated using Mixed Model Repeated Measures (MMRM) model with treatment, geographic region (US/OUS), previous therapy (yes/no), baseline value, visit, and the interaction treatment-by-visit as fixed factors, covariance structure = unstructured.</description>
        <time_frame>Baseline, Week 16</time_frame>
        <population>All participants who received at least one dose of study drug who had baseline and at least one post-baseline Patient Global Assessment observation.</population>
        <group_list>
          <group group_id="O1">
            <title>Induction: Placebo</title>
            <description>Induction: Placebo administered SC Q8W during Induction period.</description>
          </group>
          <group group_id="O2">
            <title>Induction: 30 mg Mirikizumab</title>
            <description>Induction: 30 mg Mirikizumab administered SC Q8W during Induction period.</description>
          </group>
          <group group_id="O3">
            <title>Induction: 100 mg Mirikizumab</title>
            <description>Induction: 100 mg Mirikizumab administered SC Q8W during Induction period.</description>
          </group>
          <group group_id="O4">
            <title>Induction: 300 mg Mirikizumab</title>
            <description>Induction: 300 mg Mirikizumab administered SC Q8W during Induction period.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change (Improvement) From Baseline on the Patient Global Assessment</title>
          <description>The Patient's Global Assessment of Disease Severity is a single-item participant-reported outcome measure on which participants are asked to rate the severity of their psoriasis &quot;today&quot; from 0 (Clear) = no psoriasis, to 5 (Severe) = the worst their psoriasis has ever been. Least Square (LS) Mean was calculated using Mixed Model Repeated Measures (MMRM) model with treatment, geographic region (US/OUS), previous therapy (yes/no), baseline value, visit, and the interaction treatment-by-visit as fixed factors, covariance structure = unstructured.</description>
          <population>All participants who received at least one dose of study drug who had baseline and at least one post-baseline Patient Global Assessment observation.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.35" spread="0.16"/>
                    <measurement group_id="O2" value="2.24" spread="0.16"/>
                    <measurement group_id="O3" value="2.91" spread="0.16"/>
                    <measurement group_id="O4" value="2.82" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.90</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.22</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>2.56</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.22</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>2.47</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.22</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline on the Dermatology Life Quality Index (DLQI) Total Score</title>
        <description>The DLQI is a patient-reported, 10-question, quality-of-life questionnaire that covers 6 domains including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include &quot;Not at all,&quot; &quot;A little,&quot; &quot;A lot,&quot; and &quot;Very much,&quot; with corresponding scores of 0, 1, 2, and 3 respectively. Questions 3-10 also have an additional response category of &quot;Not relevant&quot; which is scored as &quot;0&quot;. For all questions, if unanswered the question is scored as &quot;0&quot;. Totals range from 0 to 30 (less to more impairment). Least Square (LS) Mean was calculated using Mixed Model Repeated Measures (MMRM) model with treatment, geographic region (US/OUS), previous therapy (yes/no), baseline value, visit, and the interaction treatment-by-visit as fixed factors, covariance structure = unstructured.</description>
        <time_frame>Baseline, Week 16</time_frame>
        <population>All participants who received at least one dose of study drug who had baseline and at least one post-baseline DLQI observation.</population>
        <group_list>
          <group group_id="O1">
            <title>Induction: Placebo</title>
            <description>Induction: Placebo administered SC Q8W during Induction period.</description>
          </group>
          <group group_id="O2">
            <title>Induction: 30 mg Mirikizumab</title>
            <description>Induction: 30 mg Mirikizumab administered SC Q8W during Induction period.</description>
          </group>
          <group group_id="O3">
            <title>Induction: 100 mg Mirikizumab</title>
            <description>Induction: 100 mg Mirikizumab administered SC Q8W during Induction period</description>
          </group>
          <group group_id="O4">
            <title>Induction: 300 mg Mirikizumab</title>
            <description>Induction: 300 mg Mirikizumab administered SC Q8W during Induction period.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline on the Dermatology Life Quality Index (DLQI) Total Score</title>
          <description>The DLQI is a patient-reported, 10-question, quality-of-life questionnaire that covers 6 domains including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include &quot;Not at all,&quot; &quot;A little,&quot; &quot;A lot,&quot; and &quot;Very much,&quot; with corresponding scores of 0, 1, 2, and 3 respectively. Questions 3-10 also have an additional response category of &quot;Not relevant&quot; which is scored as &quot;0&quot;. For all questions, if unanswered the question is scored as &quot;0&quot;. Totals range from 0 to 30 (less to more impairment). Least Square (LS) Mean was calculated using Mixed Model Repeated Measures (MMRM) model with treatment, geographic region (US/OUS), previous therapy (yes/no), baseline value, visit, and the interaction treatment-by-visit as fixed factors, covariance structure = unstructured.</description>
          <population>All participants who received at least one dose of study drug who had baseline and at least one post-baseline DLQI observation.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.07" spread="0.69"/>
                    <measurement group_id="O2" value="-9.19" spread="0.71"/>
                    <measurement group_id="O3" value="-10.18" spread="0.69"/>
                    <measurement group_id="O4" value="-9.64" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-8.12</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.98</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-9.11</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.97</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-8.57</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.98</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline on the 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) and Mental Component Summary (MCS) Scores</title>
        <description>The SF-36 is a health-related survey that assesses participant's quality of life and consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems and emotional problems, general health, mental health, social functioning, vitality, and 2 component scores (MCS and PCS). MCS consisted of social functioning, vitality, mental health, and role-emotional scales. PCS consisted of physical functioning, bodily pain, role-physical, and general health scales. Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with higher scores indicating better health status or functioning. Least Squares Mean (LS Mean) was calculated using Analysis of covariance (ANCOVA) model with treatment, geographic region (US/OUS), and previous therapy (yes/no) as fixed factors and baseline value as covariate.</description>
        <time_frame>Baseline, Week 16</time_frame>
        <population>All participants who received at least one dose of study drug with a baseline value and at least 1 post-baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>Induction: Placebo</title>
            <description>Induction: Placebo administered SC Q8W during Induction period.</description>
          </group>
          <group group_id="O2">
            <title>Induction: 30 mg Mirikizumab</title>
            <description>Induction: 30 mg Mirikizumab administered SC Q8W during Induction period.</description>
          </group>
          <group group_id="O3">
            <title>Induction: 100 mg Mirikizumab</title>
            <description>Induction: 100 mg Mirikizumab administered SC Q8W during Induction period</description>
          </group>
          <group group_id="O4">
            <title>Induction: 300 mg Mirikizumab</title>
            <description>Induction: 300 mg Mirikizumab administered SC Q8W during Induction period.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline on the 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) and Mental Component Summary (MCS) Scores</title>
          <description>The SF-36 is a health-related survey that assesses participant's quality of life and consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems and emotional problems, general health, mental health, social functioning, vitality, and 2 component scores (MCS and PCS). MCS consisted of social functioning, vitality, mental health, and role-emotional scales. PCS consisted of physical functioning, bodily pain, role-physical, and general health scales. Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with higher scores indicating better health status or functioning. Least Squares Mean (LS Mean) was calculated using Analysis of covariance (ANCOVA) model with treatment, geographic region (US/OUS), and previous therapy (yes/no) as fixed factors and baseline value as covariate.</description>
          <population>All participants who received at least one dose of study drug with a baseline value and at least 1 post-baseline value.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.28" spread="0.87"/>
                    <measurement group_id="O2" value="2.39" spread="0.90"/>
                    <measurement group_id="O3" value="2.74" spread="0.88"/>
                    <measurement group_id="O4" value="1.52" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.23" spread="0.84"/>
                    <measurement group_id="O2" value="4.58" spread="0.88"/>
                    <measurement group_id="O3" value="4.40" spread="0.85"/>
                    <measurement group_id="O4" value="5.09" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Mental Component Summary (MCS)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.009</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>2.11</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.24</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Mental Component Summary (MCS)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>2.74</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.22</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Mental Component Summary (MCS)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.087</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.52</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.24</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Physical Component Summary</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>3.35</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.20</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Physical Component Summary</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>3.16</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.18</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Physical Component Summary</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>3.86</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.19</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics (PK): Area Under the Curve (AUC) of Mirikizumab From Baseline Through Week 104</title>
        <description>Pharmacokinetics (PK): Area Under the Curve (AUC) of Mirikizumab From Baseline through Week 104</description>
        <time_frame>Week 0, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 32, Week 40, Week 48, Week 52, Week 56, Week 64, Week 72, Week 80, Week 88, Week 96, Week 100, Week 104</time_frame>
        <population>All participants who received at least one dose of study drug and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>30 mg Mirikizumab Q8W to 30 mg Mirikizumab PRN</title>
            <description>Participants received 30 mg mirikizumab as needed (PRN) during the maintenance period.
Participants had ≥ PASI 90 at Week 16 after receiving 30 mg mirikizumab Q8W during induction period.</description>
          </group>
          <group group_id="O2">
            <title>100 mg Mirikizumab Q8W to 100 mg Mirikizumab PRN</title>
            <description>Participants received 100 mg mirikizumab as needed (PRN) during the maintenance period.
Participants had ≥ PASI 90 at Week 16 after receiving 100 mg mirikizumab Q8W during induction period.</description>
          </group>
          <group group_id="O3">
            <title>300 mg Mirikizumab Q8W to 300 mg Mirikizumab PRN</title>
            <description>Participants received 300 mg mirikizumab as needed (PRN) during the maintenance period.
Participants had ≥ PASI 90 at Week 16 after receiving 300 mg mirikizumab Q8W during induction period.</description>
          </group>
          <group group_id="O4">
            <title>Placebo to 300 mg Mirikizumab Q8W</title>
            <description>Participants received 300 mg mirikizumab Q8W during the maintenance period.
Participants had received placebo during induction period.</description>
          </group>
          <group group_id="O5">
            <title>30 mg Mirikizumab Q8W to 300 mg Mirikizumab Q8W</title>
            <description>Participants received 300 mg mirikizumab Q8W during the maintenance period.
Participants had &lt; PASI 90 at Week 16 after receiving 30 mg mirikizumab Q8W during induction period.</description>
          </group>
          <group group_id="O6">
            <title>100 mg Mirikizumab Q8W to 300 mg MirikizumabQ8W</title>
            <description>Participants received 300 mg mirikizumab Q8W during the maintenance period.
Participants had &lt; PASI 90 at Week 16 after receiving 100 mg mirikizumab Q8W during induction period.</description>
          </group>
          <group group_id="O7">
            <title>300 mg Mirikizumab Q8W to 300 mg Mirikizumab Q8W</title>
            <description>Participants received 300 mg mirikizumab SC Q8W during Induction period.
Participants had &lt; PASI 90 at Week 16 continued to receive 300 mg mirikizumab SC Q8W during maintenance period.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (PK): Area Under the Curve (AUC) of Mirikizumab From Baseline Through Week 104</title>
          <description>Pharmacokinetics (PK): Area Under the Curve (AUC) of Mirikizumab From Baseline through Week 104</description>
          <population>All participants who received at least one dose of study drug and had evaluable PK data.</population>
          <units>nanogram*hour per milliliter (ng*hr/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="34"/>
                <count group_id="O6" value="21"/>
                <count group_id="O7" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.22" spread="46.33"/>
                    <measurement group_id="O2" value="8.94" spread="79.19"/>
                    <measurement group_id="O3" value="22.96" spread="55.80"/>
                    <measurement group_id="O4" value="46.4" spread="62.8"/>
                    <measurement group_id="O5" value="34.83" spread="92.13"/>
                    <measurement group_id="O6" value="47.66" spread="70.08"/>
                    <measurement group_id="O7" value="51.30" spread="43.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up To 120 Weeks</time_frame>
      <desc>All participants who received at least one dose of study drug.Gender specific events only occurring in male or female participants have had the number of participants at risk adjusted accordingly.</desc>
      <group_list>
        <group group_id="E1">
          <title>Induction: Placebo</title>
          <description>Induction: Participants received placebo SC Q8W during Induction period.</description>
        </group>
        <group group_id="E2">
          <title>Induction: 30 mg Mirikizumab Q8W</title>
          <description>Induction: Participants received 30 mg mirikizumab Q8W during Induction period.</description>
        </group>
        <group group_id="E3">
          <title>Induction:100 mg Mirikizumab Q8W</title>
          <description>Induction: Participants received 100 mg mirikizumab SC Q8W during Induction period.</description>
        </group>
        <group group_id="E4">
          <title>Induction: 300 mg Mirikizumab Q8W</title>
          <description>Induction: Participants received 300 mg mirikizumab SC Q8W during Induction period.</description>
        </group>
        <group group_id="E5">
          <title>Maintenance: 30 mg Mirikizumab Q8W to 30 mg Mirikizumab PRN</title>
          <description>Maintenance:
Participants received 30 mg mirikizumab as needed (PRN) during the maintenance period.
Participants who had ≥ PASI 90 at Week 16 after receiving 30 mg mirikizumab Q8W during induction period.</description>
        </group>
        <group group_id="E6">
          <title>Maintenance: 100 mg Mirikizumab Q8W to 100 mg Mirikizumab PRN</title>
          <description>Maintenance:
Participants received 100 mg mirikizumab as needed (PRN) during the maintenance period.
Participants had ≥ PASI 90 at Week 16 after receiving 100 mg mirikizumab Q8W during induction period.</description>
        </group>
        <group group_id="E7">
          <title>Maintenance: 300 mg Mirikizumab Q8W to 300 mg Mirikizumab PRN</title>
          <description>Maintenance:
Participants received 300 mg mirikizumab as needed (PRN) during the maintenance period.
Participants had ≥ PASI 90 at Week 16 after receiving 300 mg mirikizumab Q8W during induction period.</description>
        </group>
        <group group_id="E8">
          <title>Maintenance: Placebo to 300 mg Mirikizumab Q8W</title>
          <description>Maintenance:
Participants received 300 mg mirikizumab Q8W during the maintenance period. Participants had received placebo during induction period.</description>
        </group>
        <group group_id="E9">
          <title>Maintenance: 30 mg Mirikizumab Q8W to 300 mg Mirikizumab Q8W</title>
          <description>Maintenance:
Participants received 300 mg mirikizumab Q8W during the maintenance period. Participants had &lt; PASI 90 at Week 16 after receiving 30 mg mirikizumab Q8W during induction period.</description>
        </group>
        <group group_id="E10">
          <title>Maintenance: 100 mg Mirikizumab Q8W to 300 mg MirikizumabQ8W</title>
          <description>Maintenance:
Participants received 300 mg mirikizumab Q8W during the maintenance period. Participants had &lt; PASI 90 at Week 16 after receiving 100 mg mirikizumab Q8W during induction period.</description>
        </group>
        <group group_id="E11">
          <title>Maintenance: 300 mg Mirikizumab Q8W</title>
          <description>Maintenance:
Participants who had &lt; PASI 90 at Week 16 continued to receive 300 mg mirikizumab SC Q8W during maintenance period.</description>
        </group>
        <group group_id="E12">
          <title>300 mg Mirikizumab Q8W-Rescue</title>
          <description>Participants received 300 mg Q8W mirikizumab during rescue.</description>
        </group>
        <group group_id="E13">
          <title>30 mg Mirikizumab Q8W to 30 mg Mirikizumab PRN-Follow-up</title>
          <description>Follow-up: Participants did not receive drug during the follow-up period.</description>
        </group>
        <group group_id="E14">
          <title>100 mg Mirikizumab Q8W to 100 mg Mirikizumab PRN-Follow-up</title>
          <description>Follow-up: Participants did not receive drug during the follow-up period.</description>
        </group>
        <group group_id="E15">
          <title>300 mg Mirikizumab Q8W to 300 mg Mirikizumab PRN-Follow-up</title>
          <description>Follow-up: Participants did not receive drug during the follow-up period.</description>
        </group>
        <group group_id="E16">
          <title>Placebo to 300 mg Mirikizumab Q8W-Follow-up</title>
          <description>Follow-up: Participants did not receive drug during the follow-up period.</description>
        </group>
        <group group_id="E17">
          <title>30 mg Mirikizumab Q8W to 300 mg Mirikizumab Q8W-Follow-up</title>
          <description>Follow-up: Participants did not receive drug during the follow-up period.</description>
        </group>
        <group group_id="E18">
          <title>100 mg Mirikizumab Q8W to 300 mg Mirikizumab Q8W-Follow-up</title>
          <description>Follow-up: Participants did not receive drug during the follow-up period.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 22.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Enlarged uvula</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Endocarditis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Intraocular melanoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Nasal septal operation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 22.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="20" subjects_at_risk="30"/>
                <counts group_id="E7" subjects_affected="23" subjects_at_risk="34"/>
                <counts group_id="E8" subjects_affected="38" subjects_at_risk="50"/>
                <counts group_id="E9" subjects_affected="28" subjects_at_risk="34"/>
                <counts group_id="E10" subjects_affected="18" subjects_at_risk="21"/>
                <counts group_id="E11" subjects_affected="13" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="9" subjects_at_risk="10"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E18" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E9" events="2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Abdominal tenderness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="3" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Periodontal disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E9" events="3" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" events="15" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E3" events="14" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E4" events="9" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E5" events="9" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" events="6" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E7" events="3" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E8" events="92" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E9" events="67" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E10" events="31" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="39" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="4" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="6" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E10" events="4" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E10" events="2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hyperplastic cholecystopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Body tinea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E11" events="4" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Erythema migrans</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Helicobacter infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hepatitis a</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hepatitis e</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="1" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="52"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="51"/>
                <counts group_id="E3" events="8" subjects_affected="6" subjects_at_risk="51"/>
                <counts group_id="E4" events="10" subjects_affected="8" subjects_at_risk="51"/>
                <counts group_id="E5" events="8" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E7" events="10" subjects_affected="7" subjects_at_risk="34"/>
                <counts group_id="E8" events="26" subjects_affected="15" subjects_at_risk="50"/>
                <counts group_id="E9" events="25" subjects_affected="12" subjects_at_risk="34"/>
                <counts group_id="E10" events="13" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E11" events="12" subjects_affected="5" subjects_at_risk="15"/>
                <counts group_id="E12" events="3" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" events="2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pulpitis dental</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Tinea pedis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="51"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E6" events="6" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E8" events="9" subjects_affected="8" subjects_at_risk="50"/>
                <counts group_id="E9" events="7" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E10" events="6" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E11" events="2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Urethritis chlamydial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E8" events="5" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E10" events="2" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E11" events="3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Vulvovaginal candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Maternal exposure during pregnancy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Tooth fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E9" events="4" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="7" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="5" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E9" events="5" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E10" events="5" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Electrocardiogram qt prolonged</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E8" events="4" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E10" events="4" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E9" events="10" subjects_affected="8" subjects_at_risk="34"/>
                <counts group_id="E10" events="4" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Exostosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Muscle tightness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Psoriatic arthropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="3" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Tenosynovitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Skin papilloma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" events="5" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E8" events="4" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E9" events="4" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Prostatomegaly</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Scrotal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Vulvovaginal pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E9" events="8" subjects_affected="5" subjects_at_risk="34"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Onycholysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Stasis dermatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cataract operation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Sinus operation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Tooth extraction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E7" events="4" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E8" events="4" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E10" events="5" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E18" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
      <email>ClinicalTrials.gov@lilly.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

